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Abstract
Background:  Vascular calcification is associated with metabolic syndrome, diabetes,
hypertension, atherosclerosis, chronic kidney disease, and end stage renal disease. Each of the
above contributes to an accelerated and premature demise primarily due to cardiovascular disease.
The above conditions are associated with multiple metabolic toxicities resulting in an increase in
reactive oxygen species to the arterial vessel wall, which results in a response to injury wound
healing (remodeling). The endothelium seems to be at the very center of these disease processes,
acting as the first line of defense against these multiple metabolic toxicities and the first to
encounter their damaging effects to the arterial vessel wall.
Results: The pathobiomolecular mechanisms of vascular calcification are presented in order to
provide the clinician – researcher a database of knowledge to assist in the clinical management of
these high-risk patients and examine newer therapies. Calciphylaxis is associated with medial
arteriolar vascular calcification and results in ischemic subcutaneous necrosis with vulnerable skin
ulcerations and high mortality. Recently, this clinical syndrome (once thought to be rare) is
presenting with increasing frequency. Consequently, newer therapeutic modalities need to be
explored. Intravenous sodium thiosulfate is currently used as an antidote for the treatment of
cyanide poisioning and prevention of toxicities of cisplatin cancer therapies. It is used as a food and
medicinal preservative and topically used as an antifungal medication.
Conclusion: A discussion of sodium thiosulfate's dual role as a potent antioxidant and chelator of
calcium is presented in order to better understand its role as an emerging novel therapy for the
clinical syndrome of calciphylaxis and its complications.
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Background
Atherosclerosis and vascular ossification – calcification
(VOC) date to the time of the ancient Egyptians [1].
In the initial descriptive phase before the various hypoth-
eses regarding the pathogenesis of atherosclerosis
emerged, prominent pathologists of the time emphasized
the bone like changes and used the terms ossification and
petrification of atherosclerotic lesions.
Benivieni A. in 1507 and Fallopio G. (Fallopius) in 1575
were the first to record for posterity their initial descrip-
tions of atherosclerosis. Fallopius, in 1575, described a
degeneration of arteries into bone, which physicians of
the time called ossification of the arteries [2]. In 1863, Vir-
chow labeled the vascular changes as "ossification, not
mere calcification, occurring by the same mechanism by
which an osteophyte forms calcium on the surface of
bone" [3]. During the 1800s a widely held concept was
that VOC might be a protective mechanism to prevent
aortic aneurysms from rupturing. In 1906, Bunting was
able to demonstrate the presence of bone marrow con-
taining its classical cellular contents including osteoclasts
within a sclerotic aorta. He frequently debated the finding
of ossification within the arterial vessel wall (AVW) and
supported the finding that ossification was not a rare
occurrence; rather it was just not specifically searched for
at the time of autopsy [4].
It is currently widely accepted that vascular cells play an
active role in osteoid formation and the ossification proc-
ess to result in VOC. [5-10]
Newer imaging techniques such as the ultrafast computed
tomography, intravascular ultrasound, and emerging data
on magnetic resonance imaging are rapidly changing the
way we view VOC. These newer techniques (as compared
to VOC in radiographs) (figure 1) demonstrate that VOC
is not just a degenerative end-stage passive process associ-
ated with aging, but a dynamic and regulated event, which
serves as a marker and occurs early in the natural history
of atherosclerosis [11-13]. Currently, it is felt that coro-
nary artery calcification is not a late, degenerative, end-
stage process, but is widespread even in the early, positive,
outward remodeling phase and is predictive of cardiac
events prior to the development of stenotic lesions [11].
VASCULAR OSSIFICATION – 
CALCIFICATION (VOC)
VOC represents a pathologic secondary ossification site or
dystrophic calcification primarily in the arterial vascula-
ture in a response to injury mechanism, just as the body
responds to the traumatic event of a fractured bone and/
or repair of the chondral injury associated with the patho-
genesis of osteoarthritis (table 1). In the vasculature this
injury is a result of chronic injurious stimuli associated
with multiple metabolic toxicities and their associated
reactive oxygen species (ROS) generated in the accelerated
atherosclerosis (atheroscleropathy) of the metabolic syn-
drome (metS) and type 2 diabetes mellitus (T2DM), and
non-diabetic atherosclerosis (figure 2). There is a recapit-
ulation of embryonic genetic memory associated with this
reparative – protective mechanism. In atheroscleropathy
and non-diabetic atherosclerosis, the multiple metabolic
toxicities and the resultant – parallel ROS, via stimulation
of the essential and omnipotent nuclear factor (NFkap-
paB), which activates the downstream inflammatory
mediators TNFalpha, IL-1, IL-6, and other inflammatory
markers such as C-reactive protein (CRP). VOC in its early
stages develops by a process of matrix vesicle formation
usually at the base of the lipid core in the intima of athero-
matous plaques (figure 3). These matrix vesicles are then
partially replaced with osteoid synthesized by osteoblast-
like cells of mesenchymal origin, such as the vascular
smooth muscle cell (VSMC) or pericyte. The subsequent
bone mineralization is dependent on neovascularization
– angiogenesis from the adventitial vasa vasorum (Vv),
which leads to formation of mature bone tissue in type Vb
atherosclerotic plaques (figure 4) [5,14-16].
This orderly transformation of ossification has been dem-
onstrated to occur in vitro by vascular mesenchymal cells,
which undergo a transformation of monolayer growth to
swirls, to ridges to a labyrinthine structure [16]
The vasa vasorum's guardian angel: the pericyte and its 
important role in VOC
The role of the Vv seems crucial to the development of
VOC and its resultant alteration regarding bone formation
within the osteoid tissue of the fibrocalcific plaques of
atherosclerosis. The medial and intima Vv are derived pri-
marily from the adventitial layer of the artery. The Vv acts
as a custom delivery system to supply the media and inti-
mal layers with oxygen and nutrients as the atheroscle-
rotic artery undergoes the positive outward remodeling.
These angiogenic vessels also serve as a conduit delivering
systemic hormones, cytokines and inflammatory cells to
the remodeling media and the atherosclerotic intimal dis-
ease of atherosclerosis including ossification. Of particu-
lar importance is vital role of the Vv capillary endothelium
and its guardian, multipotential, stem cell-like, support-
ive, mesenchymal cell the pericyte [1,5,17] (table 2) (fig-
ure 1, 5). The location of VOC in these arteries is both in
the medial and intimal layers. It is important to note that
in health the Vv normally penetrates the media but not
the intima. In disease the Vv invade excessively not only
the media but also the intima and this may help to explain
the detrimental process of intimal ossification.Cardiovascular Diabetology 2005, 4:4 http://www.cardiab.com/content/4/1/4
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Bone siloprotein synthesized by the osteoblast-like VSMC
has recently been shown to be an angiogenic protein capa-
ble of inducing neovascularization by interacting with the
alpha v beta 3 integrin [18]. Even more exciting is the find-
ing that the endothelial pericyte is capable of synthesizing
this non-collagenous angiogenic factor as well as being
related to ossification of atherosclerotic plaques.
VOC IN metS AND T2DM
Overview
Long before the development of overt T2DM there exists a
pro-atherosclerotic process within the arterial vessel wall
(AVW) [15,16]. The metS is associated with multiple met-
abolic toxicities referred to as the A-FLIGHT-U toxicities,
which result in the production of ROS (table 3). Each of
these excess toxic substrates is capable of generating ROS
but in the metS they may act synergistically to result in
perturbations of the AVW and contribute to a premature
atherosclerosis, which has been termed atheroscleropathy
Coronary artery calcification Figure 1
Coronary artery calcification. This image demonstrates coronary artery calcification. This 68 year-old Caucasian male with 
CAD, congestive heart failure and angina was found at autopsy to have a complete occlusion of the LAD with thrombus. 
Known T2DM of 8 years duration and Htn of 10 years duration with normal CA++ and Pi, BUN 32 mg/dL, creatinine 1.8 mg/dL, 
proteinuria trace to +1, total cholesterol 198 mg/dL, and triglycerides 398 mg/dLCardiovascular Diabetology 2005, 4:4 http://www.cardiab.com/content/4/1/4
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(ASO) [19,20]. This is why many patients with overt
T2DM often present with acute coronary syndromes and
why T2DM should be considered a coronary heart disease
(CHD) risk equivalent according to the National
Cholesterol Educational Program Adult Treatment Panel
III (NCEP ATP III) guidelines.
Hyperinsulinemia, Insulin-like growth factor-1 (IGF-1), and 
Amylin (IAPP)
Insulin, IGF-1, and amylin are known to be elevated in the
insulin resistance (IR) and metS patient [21]. Insulin has
been long known be a growth factor and is a stimulus for
hepatic synthesis of IGF-1, which may be implicated in
the accelerated ossification in ASO. There is a human gene
polymorphism with a phenotype described as the Benar-
dinelle lipoatrophic syndrome more commonly referred
to as lipoatrophic diabetes and this syndrome is associ-
ated with manifestations of acanthosis nigricans, general-
ized lipoatrophy, hirsutism, muscle hypertrophy,
intellectual impairment, IR diabetes mellitus with major
diet-dependent type V hypertriglyceridemia, and an
increase in bone density, thus implying osteogenesis [22].
In addition to insulin and IGF-1, there is another beta cell
derived islet hormone that is elevated in IR, metS, predia-
betes, and early T2DM termed amylin or islet amyloid
polypeptide. Amylin may be considered to be the fraternal
twin of insulin and has recently been shown to be a phys-
iologic regulator of bone remodeling through favoring
bone formation, while inhibiting bone resorption and
thus is osteogenic [23] (table 3).
Hypertension (Htn)
Htn is the second leading cause of ESRD after diabetes.
Hypertension plays an important role in the ASO associ-
ated with metS and T2DM, as atherosclerosis is non-exist-
ent in the pulmonary arterial tree and the venous system,
due to a lower systemic intravascular pressure. Htn may be
considered toxic to the AVW and is known to be associ-
ated with VOC (table 3) [19,20,24]. Mehrotra R and col-
leagues have recently demonstrated that hypertension
plays a more putative role in the association of coronary
artery calcification than do levels of serum calcium, phos-
phorus, parathyroid hormone, and 1,25 di-hydroxy vita-
min D levels in T2DM patients not requiring dialysis [25]
Hyperlipidemia – Dyslipidemia and the Lipid Triad
The lipid triad of the metS and T2DM consists of an eleva-
tion in VLDL-C or triglycerides, small dense atherogenic
LDL-C, and a decrease in HDL-C. Once these lipids
become modified through oxidation in a milieu of
increased ROS from the synergistic effect of the associated
A-FLIGHT-U metabolic toxicities, they are a predictive
determinate of osteogenesis within the media and intima
of the AVW. The earliest changes associated of osteogene-
sis occur at the base of the lipid core in areas of necrotic-
apoptotic macrophages and are associated with ROS and
inflamation (figure 3). [1,19,20,26,27].
Hyperglycemia – Glucotoxicity: Impaired glucose 
tolerance (IGT) – impaired fasting glucose (IFG) – overt 
T2DM
Elevated glucose levels (glucotoxicity) have been shown
to be a direct sensitizer for osteogenesis [28,29]. In vitro
studies with VSMCs and high glucose have been shown to
induce cell proliferation and expression of osteopontin,
while hypoxia seemed to have an additive effect [28,29].
Even though it is clinically known that diabetes is associ-
ated with an increase in medial VOC, the pathogenesis is
not completely understood. Glucotoxicity seems to play
an important role by transforming VSMCs and possibly
pericytes into osteoblast-like cells (figure 6) [19,28,29].
Ishimura E et al have nicely demonstrated the importance
of controlling HbA1c levels. They were able to demon-
strate that for every 1 percent increase in HbA1c there was
a 2.1 fold increase in the risk of VOC [30]. Poor glycemic
Table 1: Tissue wound injury: a common link between two chronic diseases: OSTEOATHEROITIS and OSTEOARTHRITIS.
T Tissue wound healing: a recapitulation of embryologic genetic memory
I Injury – Inflammation: OSTEOATHEROITIS – OSTEOARTHRITIS
G Granulation tissue formation (angiogenesis)
E Endothelial cell activation, proliferation, migration: ANGIOGENESIS
R Remodeling of the AVW: initially positive outward remodeling and over time a chronically negative inward arterial remodeling (see 
Scar contracture).
Repair.
Restructure.
Resolution: results, only if the chronic injurious stimuli and sensitizers are removed from the endothelial, intimal, and medial layers of 
the arterial vessel wall.
The above 4 (R's): activate pleuripotent mesenchymal stem-cell pericytes and VSMCs to produce bone morphogenic proteins, which 
are also activated by (I): Injury and Inflammation with resulting inflammatory cytokines such as TNF alpha, IL-6 and decreased IL-10.
SS c a r : contracture and negative remodeling resulting in stenosis.
AVW stiffness even without ossification.Cardiovascular Diabetology 2005, 4:4 http://www.cardiab.com/content/4/1/4
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The central role of the endothelium in VOC and atherosclerosis Figure 2
The central role of the endothelium in VOC and atherosclerosis. This image portrays the endothelium as the first line 
of defense against multiple injurious stimuli. Most of the injurious stimuli are represented by the A-FLIGHT-U toxicities found 
in table 3. When discussing the role of VOC and how it ties into atherosclerosis and the accelerated ASO associated with 
metS, prediabetes, and overt T2DM it is important to include the various interactions of A-FLIGHT-U toxicities with the asso-
ciated ROS and the sensitizers for calcium deposition and ossification (Ca++, Pi, PTH) within the AVW (both the media and 
intima) in table 5. The role of ROS, inflammation monocyte-macrophage foam cells undergoing apoptosis – necrosis with crea-
tion of a nidus and the stimuli for the VSMC and pericyte following the neovascularization (Vv) of the media and intima to 
result in osteoid formation and later the mineralization within these atherosclerotic plaques. This image also portrays the pos-
sible role for nanobacteria in addition to C. pneumonia as well as other bacteria and viral infections as possible contributing fac-
tors for the ossification process.Cardiovascular Diabetology 2005, 4:4 http://www.cardiab.com/content/4/1/4
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control seemed to be of greater importance than calcium
and phosphate concentrations.
VOC in T2DM involves primarily the media of the AVW,
however depending on the degree of underlying ASO; it
may frequently involve the intima in those arteries where
there is a more extensive involvement of atherosclerosis
due to a deeper penetration of the adventitial Vv [1].
Medial artery calcification has been shown to be a strong
independent predictor of cardiovascular mortality in
patients with newly diagnosed T2DM [31].
In a clinical longitudinal study of 4,553 Pima Indians the
risk factors for medial artery calcification in T2DM were
impaired vibration perception, long duration of diabetes,
and high glucose concentrations as compared to non-dia-
betic matched controls, whose risk factors for VOC were
age, male gender, and high serum cholesterol [32].
Matrix vesicle formation at the base of the lipid core Figure 3
Matrix vesicle formation at the base of the lipid core. This image depicts the formation of matrix vesicles at the base of 
the lipid core in an atherosclerotic plaque. These vesicles are generated through the wound healing process and act as a nidus 
for later plaque ossification. A 32 year-old male smoker killed in a motorcycle accident. Left anterior descending coronary 
artery. Note the basophilic staining at the base of the lipid core (starred) and surrounding areas. This area represents early 
changes of atheromatous ossification. Coronary artery calcification may not be detected until later in life, however this image 
portrays VOC as being an active directed process beginning early in life.
Lipid Core
*Cardiovascular Diabetology 2005, 4:4 http://www.cardiab.com/content/4/1/4
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Transitional stages in VOC Figure 4
Transitional stages in VOC. Transitional stages in vascular calcification recapitulate embryonic endochondral ossification, 
including an acellular matrix (matrix), amorphous mineralized matrix (calcified matrix), remodeling (osteoid), and following 
neovascularization of adventitial Vv vessels, complete bone tissue (bone mineralization).
Table 2: Vasa vasorum: a custom delivery system
1. Supply the media and intima with vascular mesenchymal cells:
a. The multipotential, stem cell-like cell to contribute to the substrate of cells to produce an osteoid matrix by morphogenic bone 
proteins
b. A custom delivery system for Pi, Ca++, Glucose, Insulin, IGF-1, PTH, and other activators of bone formation
2. Substrates of the Renin Angiotensin Aldosterone System.
3. Substrates of native LDL-cholesterol and modified LDL-cholesterol.
Substrates of phospholipids from systemic circulating cells.
4. Substrates for angiogenesis. The endothelial progenitor cells, as well as, the endothelial cell and the pericyte itself via migration.
5. Supply the route for the "second wave" of inflammatory cells to the intima and vulnerable shoulder regions of the plaque, fueling the 
inflammatory process. The first wave originating from the endothelial luminal surface.
6. Supply the direct route for adventitial fibroblasts and TGF-beta allowing for intimal plaque expansion.
Bone mineralization
Osteoid
Calcified matrix
Matrix
Vascular ossification - calcificationCardiovascular Diabetology 2005, 4:4 http://www.cardiab.com/content/4/1/4
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Uric Acid
Serum uric acid (SUA) has long been known for its asso-
ciation with the metS and also it's role in T2DM has
recently been discussed in length [33]. SUA is an impor-
tant substrate in the A-FLIGHT-U multiple metabolic
toxicities and contributes to the production of ROS with
resultant modification of lipoproteins as well as interfer-
ing with the normal function of the eNOS enzyme result-
ing in an uncoupling phenomenon discussed later (table
3).
Elevated SUA reflects the activity of the xanthine oxidase
enzyme and its production of ROS, which subsequently
has a positive effect on VOC. Tseng CH has been able to
show that SUA is an independent risk factor for the devel-
opment of peripheral arterial disease in T2DM [34].
Newer risk factors: Homocysteine (Hcy), inflammation (hs 
CRP), Microalbuminuria
Each of these novel risk factors plays a significant role in
metS – T2DM and contributes to the calcification of the
AVW through their association with the multiple meta-
bolic toxicities and production of ROS while contributing
to the inflammatory process (table 3).
Hcy is known to be toxic to the AVW resulting in a host of
fibrotic remodeling changes as a result of autoxidation,
VSMC activation, and proliferation, as well as the produc-
tion of ROS [35]. Li J. et al. have been recently able to
demonstrate that Hcy potentiates calcification of cultured
rat VSMCs [36].
The multipotential, pluripotent (stem cell – like), and mesenchymal pericyte Figure 5
The multipotential, pluripotent (stem cell – like), and mesenchymal pericyte. The pericyte is considered to be a dif-
ferentiated VSMC, which acts as guardian angel of the endothelial cell. It is capable of synthesizing most of the non-collagenous 
bone morphogenic proteins associated with VOC.Cardiovascular Diabetology 2005, 4:4 http://www.cardiab.com/content/4/1/4
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Mediators of inflammation such as oxidation, carbonyl
stress, C-reactive protein (CRP), and cytokines may
directly stimulate vascular calcification. Also, inflamma-
tion reduces fetuin-A, a naturally occurring inhibitor of
vascular calcification, which binds excess mineral in
serum [37].
Increased levels of CRP are significantly associated with
the presence of vascular calcification (including atherom-
atous and medial calcification) in both aorta and hand
arteries, which may indicate a relationship between
inflammation and vascular calcification in hemodialysis
patients [38]. It is of interest to note that IL-10 plays an
important role as an anti-inflammatory cytokine and is
known to be decreased in CKD and ESRD. Low monocyte
IL-10 synthesis may contribute to a chronic inflammatory
state in these patients by defective feedback inhibition of
proinflammatory cytokine production [39]. While
inflammation plays a very important role, it is important
to note that ROS occurs upstream from inflammation and
that ROS are an important mediator of the nuclear factor
kappa B [33,34].
Microalbuminuria is recognized as a surrogate marker for
systemic endothelial dysfunction [40]. Recently, micro-
albuminuria has been shown to be a strong predicting fac-
tor of medial arterial calcification independent of
nephropathy in patients with diabetes [41].
VOC IN CHRONIC KIDNEY DISEASE (CKD)
Largely due to the prevalence of T2DM and Htn, approxi-
mately 11% of the U.S. population has some manifesta-
tion of CKD. This spans the proteinuria phase with
normal renal function to advanced ESRD requiring renal
replacement therapy either by dialysis or transplantation
[42]. To better grasp this effect of CKD, the USRDS 2004
annual report has estimated there are in excess of 400,000
people undergoing some form of renal replacement ther-
apy in the U.S. [43]. CKD should be considered in the
highest-risk category for the development of cardiovascu-
lar disease (CVD) and an aggressive team approach of glo-
bal risk reduction in order to reduce the prevalence and
severity of the associated cardiovascular events should be
established by following the RAAS acronym (table 4).
CVD accounts for the largest cause of death in ESRD
patients and may range from 10 – 30 fold higher for those
patients being treated with dialysis as compared to the
general population [44]. Patients entering dialysis over
the past two decades now have a much higher incidence
of diabetes and this is up to 59% as a first or second diag-
nosis with hypertension being the second leading cause of
Table 3: The multiple metabolic toxicities of the A-FLIGHT-U acronym
Multiple injurious stimuli responsible for the production of ROS.
A Angiotensin II (also induces protein kinase C – β  isoform)
Amylin (hyperamylinemia) islet amyloid polypeptide toxicity
AGEs/AFEs (advanced glycosylation/fructosylation endproducts)
Apolipoprotein B
Antioxidant reserve compromised
Absence of antioxidant network
Aging
ADMA (Asymmetrical DiMethyl Arginine)
Adipose toxicity: Obesity toxicity – Lipid Triad (decreased HDL-C, increased triglycerides and small dense LDL-C)
Adipocytokine toxicity: Increased TNF alpha, Il-6, TGF beta, PAI-I and the increased hormones resistin, leptin and decreased adiponectin.
F Free fatty acid toxicity: Obesity toxicity – Lipid Triad
L Lipotoxicity – Hyperlipidemia – Obesity toxicity – Lipid Triad
Leptin toxicity
I Insulin toxicity (endogenous hyperinsulinemia-hyperproinsulinemia)
IGF-1 – (GH-IGF-I axis) toxicity: This may serve to increase bone metabolism within the media of the AVW
Inflammation toxicity
G Glucotoxicity (compounds peripheral insulin resistance) and induces reductive stress through the sorbitol/polyol pathway
Pseudohypoxia (increased NADH/NAD ratio)
H Hypertension toxicity
Homocysteine toxicity
hs-CRP
T Triglyceride toxicity: Obesity toxicity – Lipid Triad
U Uric Acid – Xanthine Oxidase toxicity: Uric acid is an antioxidant early in physiological range of atherogenesis and a conditional prooxidant 
late when elevated through xanthine oxidase enzyme and generation of ROS: thus generating the paradoxical (antioxidant →  prooxidant):
URATE REDOX SHUTTLE
Endothelial cell dysfunction with eNOS uncoupling, decreased eNO and increased
ROSCardiovascular Diabetology 2005, 4:4 http://www.cardiab.com/content/4/1/4
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ESRD. Higher Framingham risk scoresand an aging popu-
lation at the time of entry as a result of current technology
and newer medications are preventing earlier coronary
events and allowing them to survive and develop other
end organ disease, such as ESRD and congestive heart
failure, which are partly responsible for the increasing
number of these patients [45].
Is atherosclerosis accelerated in this patient population or
is there some other factor(s) related to the cardiovascular
toxicity associated with uremia and dialysis?
Schwarz U et al. were able to demonstrate an increased
size of the medial layer, marked increased calcification,
increased number of calcified plaques, and a decreased
lumen area in a study of 27 patients with ESRD compared
to 27 non-renal disease controls that had died due to cor-
onary atherosclerosis. Thus, there was no evidence to sug-
gest an accelerated atherosclerosis, but instead, a major
change in plaque composition with an increase in ossifi-
cation and medial enlargement [46].
Just as there are chronic injurious stimuli in atherosclero-
sis and ASO the pathology of CKD and ESRD include
additional injurious stimuli to the vascular cells of the
AVW. These include an elevation of the following: Phos-
phorus (Pi), calcium (Ca++), parathyroid hormone (PTH),
hypoxia and resultant ROS formation, and others (table
5) (figure 6). VOC is the manifestation of a complicated
systemic process that begins primarily with medial ossifi-
cation of larger and medium size arteries and progresses
to the smaller arterioles. Concurrently, there is a
development of renal osteodystrophy and ossification in
the surrounding articulations of multiple joints [osteoath-
eroitis – osteoarthritis – renal osteodystropthy (table 1)].
The clinical manifestations of VOC depend on the loca-
tion of the affected arteries and arterioles [47-50].
Sensitizers and the Cbfa-1 "protein switch" to transform mesenchymal cells into osteroblast-like cells Figure 6
Sensitizers and the Cbfa-1 "protein switch" to transform mesenchymal cells into osteroblast-like cells. This slide 
demonstrates the transformation of the pluripotent mesenchymal VSMC and pericyte into an osteoblast-like cell. It reveals the 
importance of the ossification sensitizers and core binding factor alpha-1 Cbfa-1 emphasizing their important role in VOC.
Multipotential Cell
VSMC (a mesenchymal cell)
Inflammatory cell
Pericyte
Cbfa -1
Core binding factor alpha - 1
Cbfa-1 is currently thought
To be the “switch” that turns
This mesenchymal Cell
Into an osteoblast - like Cell
Osteoblast – like Cell
ARTERIAL OSSIFICATION
Modified atherosclerosis in ESRD (highest risk for mortality)
Calciphylaxis an emerging epidemic? (poor prognosis)
Abnormal bone mineral metabolism (renal osteodystrophy)
UREMIA
Elevated Pi, PTH
II Hyperparathyroidism
Aging, AGE, and Diabetes
[ GLUCOSE ] T2DM
Ox Lipoprotein elevation
HDL-C    low
•ROS *
•Inflammatory Cytokines
•IL-1,  IL-6, TNFalpha
•Growth Factors:  TGF beta
•Ca++, Vitamin D
Sensitizers
Type I collagen: Osteopontin,
bone sialoprotein, alk-phos, and osteocalcin
VSMCCardiovascular Diabetology 2005, 4:4 http://www.cardiab.com/content/4/1/4
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Table 4: The RAAS Acronym: Redox Stress Reduction – Global risk reduction
R Reductase inhibitors (HMG-CoA). Decreasing modified LDL-cholesterol, i.e., oxidized, acetylated LDL-cholesterol. Decreasing 
triglycerides and increasing HDL-cholesterol. Improving endothelial cell dysfunction. Restoring the abnormal Lipoprotein fractions. Thus, 
decreasing the redox and oxidative stress to the arterial vessel wall and myocardium.
A AngII inhibition or receptor blockade:
ACEi-prils. ARBs-sartans. Both inhibiting the effect of angiotensin-II locally as well as systemically. Affecting hemodynamic stress through 
their antihypertensive effect as well as the deleterious effects of angiotensin II on cells at the local level – decreasing the stimulus for O2. 
production. The positive effects on microalbuminuia and delaying the progression to end stage renal disease. Plus the antioxidant effects 
within the arterial vessel wall and capillary. Antioxidant effects.
Aspirin antiplatelet, anti-inflammatory effect on the diabetic hyperactive platelet.
Adrenergic (non-selective blockade) in addition to its blockade of prorenin →  renin conversion.
Non dihydropyridine calcium channel blocker – antagonists are preferred over dihydropyridine calcium channel blockers – 
antagonists in CKD.
A Aggressive control of diabetes to HbA1c of less than 7. This usually requires combination therapy with the use of insulin secretagogues, 
insulin sensitizers (PPAR-gamma agonists), biguanides, alpha-glucosidase inhibitors, and ultimately exogenous insulin.
Decreasing modified LDL cholesterol, i.e., glycated-glycoxidated LDL cholesterol. Improving endothelial cell dysfunction. Also decreasing 
glucotoxicity and the oxidative-redox stress to the intima and pancreatic islet.
Aggressive control of blood pressure, which usually requires combination therapy.
Aggressive control of homocysteine with folic acid with its associated additional positive effect on re-coupling the eNOS enzyme 
reaction by restoring the activity of the BH4 cofactor to run the eNOS reaction via a folate shuttle mechanism and once again produce eNO.
Aggressive control of uric acid levels with xanthine oxidase inhibitors (allopurinol and oxypurinol) should be strongly considered in view 
of the prevailing literature in order to achieve more complete Global Risk Reduction
Aggressive control of hyperphosphatemia and elevated PTH and control intake of oral calcium while limiting vitamin D. Calcium 
carbonate should no longer be used as a phosphate binder in patients with calciphylaxis or patients at very high risk for developing 
calciphylaxis.
SS t a t i n s .   Improving plaque stability (pleiotropic effects) independent of cholesterol lowering. Improving endothelial cell dysfunction. 
Moreover, the indirect antioxidant anti-inflammatory effects within the islet and the arterial vessel wall promoting stabilization of the 
unstable, vulnerable islet and the arterial vessel wall.
Style. Lifestyle modification (weight loss, exercise, and change eating habits).
Stop Smoking.
Statins: Emerging information: Positive effect on the Quality of HDL-C is emerging. i.e. prevents ox HDL-C and increases HDL-C 5–10 
percent.
Table 5: Proposed regulators of VOC
Positive Regulators Negative Regulators
Minerals: Ca++ Pi, Phosphate/Pit-1 →  Cbfa-1 Fetuin-A
Vitamin D
BMP-2
Bone morphogenic protein
MGP
Matrix gammacarboxyglutamate (Gla)-protein
Inhibits BMP-2
Warfarin
Warfarin may also cause skin necrosis similar to CPLX via an 
impairment of Protein C with thrombosis in venules resulting 
in subcutaneous ischemia and Vitamin K – GLA inhibition.
GLA
gammacarboxyglutamate
Inflammation: TNFalpha, IL-6 IL-10
Oxidized – retained – modified lipids (OxLDL-C, OxVLDL beta 
lipoproteins) and Low alpha lipoproteins: HDL-C
Osteopontin: OPN
(may be a positive and negative regulator)
ROS
Oxidative-Redox Stress
Osteoprotegerin OPG?
Elevated in human atherosclerosis and CVD yet paradoxically when you 
have a mouse model with knockout of OPG there is increased 
osteoporosis and VOC.
A-FLIGHT TOXICITIES (table 3)
Glucose
Hormones: Insulin, IGF-1, Amylin, Leptin, and PTH
I or II Hyperparathyroidism
HYPOXIA activates hypoxia inducible factor Hif-1, ROS →  
Vascular angiogenesis
Vasa Vasorum:
Multipotential →  Pericyte
RANK and RANKL
These are involved but as with OPG the entire story is still evolving.
PERICYTECardiovascular Diabetology 2005, 4:4 http://www.cardiab.com/content/4/1/4
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Atherosclerotic nephropathy
Scoble JE [51] presented the term atherosclerotic neph-
ropathy in 1999, which includes abdominal atherosclero-
sis, renal artery atherosclerosis with renal artery stenosis,
and atheroembolic disease. In older age populations, it
has been estimated that atherosclerotic renal artery dis-
ease accounts for 14% (over the age of 50) and 25% of
patients (over the age of 60) with end-stage renal failure
[51,52]. With the age groups over the age of 50 and 60
(baby boom – senior boom generation) expanding at an
exponential rate in western countries we will see an
increasing number of patients with ESRD attributable to
this abnormality.
This atheroembolic phenomenon accounts for untold
cases of ischemic nephropathy with functional loss of
nephron units. Associated clinical companions of this
condition that might alert the clinician would be: rapid
increasing proteinuria, rapid deterioration of renal func-
tion, and other clinical evidence of peripheral atheroem-
bolic phenomenon in other vascular beds such as the
extremities in peripheral vascular disease (blue toe
syndrome), mesenteric thrombosis and associated gas-
trointestinal bleeding, and extra cranial cerebrovascular
atherosclerosis with associated transient ischemic epi-
sodes or overt cerebral thrombosis.
In atherosclerotic coronary artery disease we do not see
evidence of intra-myocardial atherosclerosis and likewise,
we do not find evidence of intrarenal atherosclerosis. The
renal artery may be likened to an epicardial coronary
artery when comparing these two diseases. It is currently
accepted that atherosclerotic coronary artery disease and
hypertension account for the major cause of death and
congestive heart failure in developed countries. It is time
to consider atherosclerotic renal artery disease with VOC
and associated renal artery stenosis, as well as,
hypertension as a significant cause of progressive CKD
and its progression to ESRD.
As present in any atherosclerotic lesion, VOC is known to
occur and will increase in the patient with CKD and ESRD
(especially the patients with diabetes and ASO). VOC
detected by non-invasive spiral CT scanning would alert
the clinician to the possibility of renal artery stenosis and
additionally alert the clinician to the importance for more
aggressive therapeutic measures to control the A-FLIGHT-
U toxicities (table 3) as well as to control the metabolic
toxicities of the increased known sensitizers to VOC (table
5) (figure 6).
VOC IN CALCIPHYLAXIS (CPLX) – CALCIFIC 
UREMIC ARTERIOLOPATHY (CUA)
Any discussion of VOC would be incomplete without dis-
cussing the important issue of CPLX – CUA and a better
understanding of this condition merits a janus-faced
approach. The century old CPLX – CUA clinical syn-
drome, which once was considered to be a rare clinical
phenomenon primarily associated with CKD and ESRD is
now being reported and being seen in increasing num-
bers. Part of this increase may well be due to a better
understanding and recognition of this syndrome and pre-
vious underreporting; however nephrology and dermatol-
ogy departments, and dialysis clinics throughout the U.S.
are seeing increasing numbers of this morbid – mortal
complicated clinical syndrome. As the number of patients
with CKD and ESRD continue to grow in numbers the
medical community may well see this syndrome in near
epidemic proportions (especially considering the current
obesity – metS – T2DM epidemic).
CPLX is not unique to any one country and is a global
phenomenon. As with any new and emerging clinical syn-
drome the literature is replete with multiple case reports
of this entity. In this review, an attempt is made to
increase the awareness and understanding of this malady
and provide an overview and not reference the multiple
rare and unusual case reports, unless they contribute to
the understanding of mechanisms or treatment [53-63].
Historical perspective of CPLX
Selye's initial experiments in rats set the stage for the
description of this clinical entity in humans [64]. He
hypothesized that sensitizers such as PTH or vitamin D
might condition the vasculature to VOC. After providing
the sensitization he then challenged the rats with known
provoking factors including metal salts, albumin, and
trauma, which induced calcium deposition and subse-
quent inflammatory necrosis of the skin and subcutane-
ous tissue. Over time other studies suggested alternate
contributing factors, such as those listed in table 5. The
name originated from the combination of calcium and
anaphylaxis, thus calciphylaxis, however this model does
not involve IgE mechanisms.
Byrant and White (1898) are credited as having described
the first clinical presentation in a six-month-old infant, in
which there was VOC and what they termed endarteritis
obliterans, indicating involvement of the intima [65]. It
was not until 1969 that Rees and Coles used the
terminology calciphylaxis to describe this clinical and
pathologic syndrome in man [66].
Coates (1998) coined the term calcific uremic arteriolop-
athy (CUA) as a replacement term for CPLX, since in
many instances elevations of Ca++, Pi or PTH levels are
absent [67]. Over time CUA may become the preferred
term, as this newer terminology is only six years old. The
term calciphylaxis is almost entrenched in the medical lit-
erature at this point in time; however Selye's animalCardiovascular Diabetology 2005, 4:4 http://www.cardiab.com/content/4/1/4
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model more closely parallels the dystrophic tumorous
soft tissue calcifications of uremic CPLX. His model did
not exhibit the histology consistently described with ure-
mic CPLX, i.e. small vessel calcifications and intimal
hypertrophy in association with panniculitis (lobular fat
necrosis, and inflammatory changes with neurtrophils,
lymphocytes and macrophages, and small vessel throm-
bosis or involve IgE mechanisms [54,67-69]. We favor the
term: obliterative calcific vasculopathy.
VOC in the syndrome of CPLX – CUA is an important
topic for discussion, as it is being reported at an exponen-
tial rate and especially over the past two years. The devas-
tating complication of medial vascular calcification of
small arterioles with resulting skin necrosis is rapidly
becoming a morbid complication in both the non-dia-
betic and especially the large numbers of diabetic patients
(T2DM > T1DM) undergoing renal replacement therapy
(figure 7).
Histologic changes in a patient with CPLX and ESRD Figure 7
Histologic changes in a patient with CPLX and ESRD. Breast biopsy (benign) from a non-diabetic 60-year-old Caucasian 
female with an irregular breast mass 12 months prior to the development of clinical abdominal CPLX (multiple tumorous calci-
fications in the abdominal adipose tissue and skin ulceration). These tissue sections demonstrate the underlying systemic VOC 
of calciphylaxis. Her ulcerated area on the abdomen was not biopsied due to a possibility of aggravating tissue healing. Panel a: 
Demonstrates the H&E basophilic staining of intimal VOC in a small musculoelastic artery. Panel b: Demonstrates the medial 
fluorescent-like staining (due to inverted coloration of H & E basophilic staining) of VOC in an arteriole. Note the adjacent 
venule medial VOC staining. Venular VOC – thrombosis has not been as extensively studied as the arteriole and one must con-
sider the possibility that VOC – thrombosis in the post-capillary venule may be important as the increased capillary edema and 
pressure may result in capillary endothelial dysfunction and promote an additive factor in the important role of subcutaneous 
ischemia and skin necrosis and ulceration. Note the panarteriolar involvement of the intima, media, and adventitia in the vari-
ous vessels. Panel c: Demonstrates the H & E basophilic adventitial staining of VOC in an arteriole.
Histological findings from breast biopsy 2003:
Calciphylaxis
Vascular calcification involving intima (a), media (b), adventitia (c)
ac
bCardiovascular Diabetology 2005, 4:4 http://www.cardiab.com/content/4/1/4
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The skin in CPLX
The skin lesions of CPLX present as painful violacous
(livedo reticularis) areas in the extremities, proximal
medial thighs, anterior abdomen and lateral flank areas,
the breast in females, and frequently overlie or are adja-
cent to subcutaneous tumorous calcifications in areas of
increased adipose tissue. They then progress to a black-
ened eschar, which later reveals itself on a granulating bed
and enlarges at the periphery of the ulcer. They have a ten-
dency to develop in sites of prior skin trauma, such as
abdominal scars from previous surgical incisions and may
even develop from the trauma of simple scratching of
extremities due to ESRD-associated pruritis.
It is important to recognize the clinical presentation of the
skin color changes and the neuropathic type of pain
before ulceration has developed. If we wait until skin
ulceration develops we place the CPLX patient at an
increased risk of sepsis and premature death. We should
carefully assess any palpable calcific tumorous masses in
the subcutaneous tissue in patients at high risk for CPLX.
Not all skin ulcerations are due to CPLX and therefore we
should utilize our differential diagnostic skills in
evaluating ulcers in these high-risk patients with CKD,
T2DM, and ESRD. A reasonable differential diagnosis
might include the following (table 6). Even though a skin
biopsy may show medial arteriolar calcification and atro-
phy of medial muscle layers in the arteriole, we should
keep in mind that these changes although quite specific
are not pathognomonic for CPLX.
The recent emergence of a newer skin pathology termed:
neprogenic fibrosing dermopathy may appear co-mor-
bidly with CPLX and recently it has been reported that
transforming growth factor beta-1 (TGF beta-1) may to be
related to both disorders [55]. By making an accurate and
earlier diagnosis of CPLX, a greater effort may be given by
the primary care provider and the nephrology team as well
as other specialties (dermatology and plastic surgery) to
improve the multiple A-FLIGHT-U toxicities in each
patient (table 3). Earlier treatment of each altered abnor-
mality of the associated multiple metabolic derangements
may prevent or delay the progression of this morbid mor-
tal clinical syndrome (table 4,5).
Endotheliopathy, redox stress, and reactive oxygen 
species. eNOS and eNO
The endothelium is an elegant symphony responsible for
the synthesis and secretion of several biologically active
molecules. It is responsible for regulation of vascular tone,
inflammation, lipid metabolism, vessel growth (angio-
genesis – arteriogenesis), arterial vessel wall – capillary
sub endothelial matrix remodeling, and modulation of
coagulation and fibrinolysis. One particular enzyme
system seems to act as the maestro: The endothelial nitric
oxide synthase (eNOS) enzyme and its omnipotent meta-
bolic product: endothelial nitric oxide (eNO) (figure 2,8).
Table 6: Differential diagnosis of cutaneous ulcers
Drug reactions:
Warfarin
Circulatory Disorders:
Venous stasis
Peripheral arterial disease
Necrotizing vasculitis – Collagen vascular diseases -
Infectious endocarditis with septic emboli
Cholesterol emboli
CALCIPHYLAXIS (CPLX) – CALCIFIC UREMIC ARTERIOLOPATY (CUA)
Diabetes: (T1DM – T2DM)
Peripheral neuropathy
Peripheral vascular disease accelerated atherosclerosis (atheroscleropathy) ASO Insulin injection sites (sharp trauma)
Necrobiosis lipoidica diabeticorum?
Trauma
Sharp – Blunt – pressure ulcers at pressure points due to immobilization
Thermal (Hot or Cold [cryoglobulinaemia]) – Radiation
Radiation therapy
Miscellaneous
Brown Recluse spider bite
Malignant tumors
Inflammatory Diseases
Collagen Vascular Diseases – Necrotizing vasculitis specifically SLE, systemic sclerosis (Scleroderma)
Pyoderma gangrenosum usually associated with chronic inflammatory diseases such as: ulcerative colitis, Crohn's disease, and rheumatoid 
arthritisCardiovascular Diabetology 2005, 4:4 http://www.cardiab.com/content/4/1/4
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The eNOS enzyme reaction is of utmost importance to the
normal functioning of the endothelial cell and the AVW.
When this enzyme system uncouples, the endothelium
becomes a net producer of superoxide and ROS instead of
the net production of the protective antioxidant proper-
ties of endothelial derived nitric oxide (table 7) (figure 8).
There are multiple causes for eNOS enzyme uncoupling:
The A-FLIGHT -U multiple metabolic toxicities, oxidative
– redox stress, ROS, metS, insulin resistance, prediabetes,
T2DM and T1DM, Htn, endothelin, and asymmetrical
dimethyl arginine (ADMA) [1,19,20,27,28,34,45].
The endothelial cell is important in controlling the func-
tion of small arterioles and how they may become a net
producer of ROS. This endothelial dysfunction may pre-
cede the vascular narrowing – closure, prothrombotic
state, thrombosis with resulting ischemia of the surround-
ing subcapillary interstitium, ischemic necrosis of the sub-
cutaneous adipose tissue, and skin changes of livedo
reticularis with transformation to painful necrosis, eschar
formation, and skin ulceration.
In addition to correcting the underlying multiple meta-
bolic A-FLIGHT toxicities and positive regulators of VOC
Uncoupling of the eNOS enzyme resulting in the net production of superoxide instead of the protective endothelial nitric  oxide (eNO) Figure 8
Uncoupling of the eNOS enzyme resulting in the net production of superoxide instead of the protective 
endothelial nitric oxide (eNO). This image depicts the eNOS enzyme reaction and resultant production of the protective 
antioxidant, anti-inflammatory gas product eNO. Oxygen reacts with the eNOS enzyme in which the tetrahydrobiopertin 
(BH4) cofactor has coupled nicotinamide dinucleotide phosphate reduced (NAD(P)H) enzyme with L-arginine to be converted 
to nitric oxide (NO) and L-citrulline. When eNOS uncoupling occurs the NAD(P)H enzyme reacts with O2 and the endothelial 
cell becomes a net producer of superoxide (O2
•) instead of the protective endothelial NO. This figure demonstrates the addi-
tional redox stress placed upon the arterial vessel wall and capillaries in patients with MS, PD, and overt T2DM.
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Table 7: The positive effects of eNOS and eNO
• Promotes vasodilatation of vascular smooth muscle.
• Counteracts smooth muscle cell proliferation.
• Decreases platelet adhesiveness.
• Decreases adhesiveness of the endothelial layer to monocytic WBCs (the "teflon effect").
• Anti-inflammatory effect.
• Anti-oxidant effect. It scavenges reactive oxygen species locally, and acts as a chain-breaking antioxidant to scavenge ROS.
• Anti-fibrotic effect. When NO is normal or elevated, matrix metalloproteinases (MMPs) are quiescent; conversely if NO is low, MMPs are 
elevated and active. MMPs are redox sensitive.
• NO inhibits prooxidant actions of uric acid during copper-mediated LDL oxidation.
• NO has diverse anti-atherosclerotic actions on the arterial vessel wall including antioxidant effects by direct scavenging of ROS – reactive nitrogen 
species RNS.
Sodium thiosulfate Figure 9
Sodium thiosulfate. This figure demonstrates the chemical structure of sodium thiosulfate, which is an antibrowning, reduc-
ing, and antioxidant agent: Capable of donating electrons to re-pair unpaired damaging electrons to be an effective antioxidant 
as well as a chelator of cations such as the calcium excess in calcific uremic arteriolopathy – CPLX.
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(table 3,5), a strong consideration to newer therapies
should be entertained in order to prevent, slow, and alter
the morbid – mortal natural history of the dreaded com-
plications associated with CPLX – CUA.
Future Directions
Sodium thioSulfate (STS) intravenous therapy for 
calciphylaxis: its emerging role
STS is an effective antibrowning, reducing, and antioxi-
dant agent and therefore readily donates electrons to re-
pair unpaired damaging electrons to be an effective
antioxidant in addition to it use as a chelator of cations
such as the calcium excess in CPLX – CUA (figure 9). The
following is one of many possible antioxidant reactions as
it scavenges ROS and may be responsible for producing
glutathione:
STS is known to be a chelator of cations and has been used
for over a century as an antidote for cyanide toxicity, top-
ical treatments of acne and versicolor, and recently as a
chemoprotectant against carboplatin and cisplatin toxic-
ity. Its use in the treatment of calciphylaxis has only
recently been described and its future use may become a
standard of care in the treatment of the dreaded
complications [70]. Its dual role as an antioxidant and
chelator makes STS an excellent choice for the treatment
of calciphylaxis and it will be interesting to follow future
clinical trials regarding it use.
Clinically, STS seems to have a rather intriguing rapid
response in the relief of the pain associated with CLPX
and it frequently reduces pain within the very first few
treatments (personal experience). Additionally, it seems
to promote healing of skin ulcerations especially when
used in conjunction with hyperbaeric oxygen treatments
[70].
The STS hypothesis
STS may restore endothelial cell dysfunction in CPLX
through its antioxidant actions and have a positive effect
on eNOS uncoupling and eNO generation. We have
formed a hypothesis that the rapid reduction in pain may
be due to a restoration of endothelial dysfunction
associated with this syndrome. The anitoxidant effect of
STS, given in the intravenous dosage of 12.5–25 grams
intravenous at the end of dialysis may help to restore the
dysfunctional endothelial cell and begin restoring the
endothelium's natural tendency (in health) to produce
eNO (promoting vasodilation) instead of the
dysfunctional super oxide and the resultant peroxynitrite
(promoting vasoconstriction) (figure 8)
[1,19,20,27,28,34,45].
STS could be working in two different vascular beds in the
vulnerable subcutaneous tissue, as the peripheral neuro-
nal unit is also involved with dystrophic ossification –
calcification (figure 10): The vasa nervorum and the
endoneurium of the peripheral neuronal unit [71] and the
distal small pre-capillary arterioles. These changes would
help to explain the rapid improvement of this morbid
neuritic (breathtaking, stinging, burning, and knife-like)
type of pain, as the chelation properties of STS would take
much longer (months compared to hours or days) to
restore the capabilities of the neuro-circulatory vascular
beds.
Diabetic and peripheral arterial disease patients may be
slower to respond as they are plagued with a much more
intense endothelial cell dysfunction and endothelial nitric
oxide enzyme uncoupling due to the advanced atheroscle-
rotic process and medial calcifications and associated
ischemic changes.
Undoubtedly the essential cofactor tetrahydrobiopterin
(BH4) becomes depleted during this chronic ischemia in
the subcutaneous tissue from the multiple metabolic tox-
icities. STS may have a "folate-like redox shuttle effect"
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Neuronal calciphylaxis Figure 10
Neuronal calciphylaxis. This image demonstrates not only 
medial calcification of an arteriole but also calcification of the 
epineurium of a peripheral neuronal unit within the subcuta-
neous tissue of a patient with systemic CPLX. This is from 
the same patient and breast biopsy tissue as in figure 7. Cal-
cium stains black in this von Kossa stain.Cardiovascular Diabetology 2005, 4:4 http://www.cardiab.com/content/4/1/4
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similar to the pleiotropic effects of folic acid supplemen-
tation [34] by allowing the oxidized cofactor BH3 and BH2
to undergo a restoration by the antioxidant effects of STS
to the requisite completely reduced form BH4. This may
ameliorate the underlying oxidative stress within the pre-
capillary and capillary beds of the interstitium and the
endoneurium of the peripheral neuronal units involved.
While this is only a hypothesis it seems to be clinically rel-
evant due to the clinical observation of a rapid relief of the
pain associated with CPLX.
Emerging role of nanobacteria
Currently, the multiple roles of nanotechnology and
nanobacteria are rapidly emerging and with new findings
come new ideas, which may have a significant impact
regarding the future of medicine. Nanobacteria may be a
causative agent of diseases related to the biomineraliza-
tion processes. As clinicians and scientists we must be
careful as newer hypothesis and treatments emerge. For
example even though nanobacteria have been found in
multiple disease states associated with calcium deposi-
tion, we have yet to fulfill Koch's postulates regarding
VOC. Because this information has just evolved it is
important to review some of the background in this field
of study.
We have witnessed the exciting story of H. pylori and its
causative role in ulcer disease and followed the C. pneumo-
nia story in atherosclerosis finding it to be one of the bur-
densome infectious injurious stimuli to the endothelium
that results in remodeling and atheromatous changes in
the AVW. Likewise, the new information regarding nano-
bacteria being associated with VOC is exciting and could
play a very important role in the causation of the athero-
matous process and VOC (figure 2).
Nanobacteria belong to the family of gram-negative rods
(approximately 100 fold smaller in size) and have been
recently localized in cardiovascular tissue. Miller VM et al.
have found nanometer-scale particles (ranging in size
from 30 to 100 nm) similar to those described as nano-
bacteria isolated from geological specimens and human
kidney stones. These ultra small microbes can be visual-
ized in and stained immunohistologically from calcified
human cardiovascular tissue [72]. Jelic et al. have demon-
strated the presence of nanobacteria in a mitral valve asso-
ciated with a localized calciphylaxis within mitral
vegetations from a patient with T2DM [73].
Maniscalco BS et al., have been able to demonstrate a sta-
tistically significant improvement in coronary calcium
scores (inferring a reversal of VOC) and a reduction in
angina in a group of patients with CAD and coronary
artery calcifications using thecombination of EDTA by rec-
tal suppository and a combination of multiple known
antioxidants with 500 mg tetracycline (nanobacterio-
cidal) given daily by mouth. The treatment duration was
4 months [74].
Recently the literature has been replete with the associa-
tion of periodontal disease and its relation to
cardiovascular disease and events. Whether this condition
is responsible for the activation of the chronic inflamma-
tory disease response driving the atherosclerotic process
or not remains to be seen. The recent isolation of nano-
bacterium with periodontal disease has fueled the fire of
this being a putative microorganism in the development
and progression of atherosclerotic disease and VOC [75].
Osteoporosis and VOC
The coexistence of osteoporosis, CVD, and VOC with the
aging process in humans and the concept of a shift of cal-
cium from the osseous skeleton towards the AVW have
been suggested as one of the explanations for their simul-
taneous existence [76,77].
Accumulating evidence indicates that there are similar
pathophysiological mechanisms underlying both
diseases. The A-FLIGHT-U multiple metabolic toxicities
and resultant ROS, oxidative stress, endothelial cell dys-
function, endotheliopathy, and inflammation have been
central issues in this paper regarding VOC. Each of these
is associated with a modulation of vascular and osteo-
genic cells but in an opposite manner and may act in a
synergistic manner. The finding of oxidative stress pro-
moting VOC while promoting osteoporosis may help to
explain the paradoxical parallel buildup of VOC and the
concurrent loss of bone mineralization in the osseous
skeleton [78-80]. The current evidence linking both of
these diseases is far from conclusive and additional
research is necessary to further characterize the relation-
ship between these two common illnesses as our popula-
tion of baby (senior) boomers are aging in large numbers.
One such exciting and current emerging area in vascular
biology involves the RANKL/RANK/OPG system, which
belong to the tumor necrosis factor-related family recently
discovered to be critical regulators of the immune system
and skeletal biology. RANK(L) (receptor activator of
nuclear factor kappaB (ligand) may promote and
osteoprotegerin (OPG) may protect against vascular
calcification (table 5). The mouse OPG knockout model
displays osteroporosis and increased vascular calcification
and human gene polymorphisms of OPG are currently
being defined and how they may confer an increased risk
of CAD in Caucasian men while interacting with VOC and
osteoporosis [81]. The finding that OPG levels may reflect
endothelial cell dysfunction is certainly an area under seri-
ous consideration [76,82].Cardiovascular Diabetology 2005, 4:4 http://www.cardiab.com/content/4/1/4
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CPLX and T2DM
The diabetic patient is already plagued with an underlying
accelerated atherosclerosis (atheroscleropathy (ASO)), as
well as, medial fibrosis and VOC (even if they do not
develop CKD or ESRD requiring dialysis). With the cur-
rent epidemic of obesity, metS, insulin resistance related
T2DM (diabesity) in all age groups and particularly the
aged and adolescent youth, a closer examination of this
morbid – mortal complication is in order [83-87].
If these T2DM patients do develop CKD and/or ESRD
requiring dialysis they could be at a much higher risk of
developing an even more severe form of VOC. This dual
effect of having not only T2DM related medial calcifica-
tion but also having the increased risk for the
development of medial remodeling and VOC from CKD
and/or ESRD requiring dialysis would place these individ-
uals at an extremely high risk for the development of
excessive medial arterial remodeling and VOC, as well as
arteriole remodeling and VOC, which could possibly
increase the risk of developing CPLX (figure 2, 7). Many
T2DM patients may have medial arteriolar calcification
that could be contributing to anunderlying skin necrosis
currently being attributed singularly to peripheral arterial
disease and ischemic necrosis or gangrene, when if fact
they might have coexisting arteriolar calcification contrib-
uting to their skin changes of gangrene. This dual mecha-
nism of VOC in the arterioles and conduit arteries could
be playing an important role in development of CPLX.
The treatments to date have largely consisted of careful
wound management, hyperbaric oxygen therapy [88],
and specific treatment of wound infections, which fre-
quently become systemic and result in deadly sepsis,
organ failure, and patient demise. These open ulcerations
of the skin are extremely difficult to heal and while they
remain open they place the patient at an extreme risk of
infection, as this patient population is known to have an
impaired immune system from the combination of dialy-
sis and T2DM [89]. If STS does emerge as a treatment
option for those with CPLX then a careful evaluation of
the T2DM patient with skin ulceration should be explored
and consideration given to the use of STS provided there
is evidence of an associated arteriolar calcification in addi-
tion too medial calcification of the conduit arteries. The
dual effect of STS being an antioxidant and a chelator of
calcium could have a positive outcome in promoting
healing of skin ulcerations, thus reducing the possibility
of systemic infection and furthermore result in limb sal-
vage of these high risk patients who seem to be presenting
to dialysis clinics more and more as the obesity – T2DM
epidemic continues to progress. Additionally, the use of
STS may be considered in the treatment of VOC associated
with CHD and peripheral arterial disease independent of
CKD and dialysis.
Conclusion
This review has been an attempt to increase our basic
understanding of VOC and its mechanisms in the patient
with metS, T2DM, CKD, CHD, and the syndrome of
CPLX. By improving our understanding of the
mechanisms in play we may be better equipped to prevent
many of the complications associated with VOC.
VOC is an exciting and complicated field of study and
while our understanding of this process has undergone
considerable improvement regarding its mechanisms and
understanding during the past few years, there remain
many questions to be solved and newer therapies pro-
posed to help decrease the morbid – mortal complica-
tions of this actively regulated process.
The recent publications of case reports regarding the use
of STS to treat the complications of VOC and the syn-
drome of CPLX may result in the necessary clinical trials
and the important scientific animal experiments to fully
evaluate and understand its effect. Additionally these early
published clinical results should instigate the necessary
studies to better understand the mechanisms of this
emerging treatment for calciphylaxis and its possible role
in treating VOC in patients with CHD, atherosclerosis and
atheroscleropathy in metS, and T2DM. Additionally, this
emerging treatment may have significant applications for
diabetic patients with CKD, ESRD. and VOC.
Earlier diagnosis of the patient at risk for the development
of VOC is important so that a global risk reduction pro-
gram can be initiated in order to control for the multiple
metabolic toxicities by applying the therapeutic RAAS
acronym (table 4) for the treatment and prevention of
complications [90]. While this remains a daunting task for
clinicians it can be undertaken by a team effort approach
involving our multiple resources and sub-specialties in
medicine.
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